Welcome to our dedicated page for Telix Pharmaceuticals ADR SEC filings (Ticker: TLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telix Pharmaceuticals Limited (TLX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 20-F and a series of Form 6-K reports. As a foreign private issuer listed on the Nasdaq Global Select Market, Telix uses Form 6-K to furnish key announcements originally released on the Australian Securities Exchange (ASX) to U.S. investors.
Through these filings, readers can review clinical, regulatory, and financial updates that Telix has formally submitted to the U.S. Securities and Exchange Commission. Examples referenced in recent 6-Ks include press releases on CMS granting Transitional Pass-Through status for Gozellix, revenue and operational updates, regulatory correspondence for TLX250-CDx, and clinical trial milestones such as progress in the ProstACT Global study. Each 6-K typically attaches the underlying ASX announcement as an exhibit, preserving the full text for detailed analysis.
For investors evaluating Telix’s radiopharmaceutical portfolio, SEC filings complement ASX disclosures by providing an official record of developments in products like Illuccix, Gozellix, TLX101-CDx, TLX250-CDx, and therapeutic candidates in oncology and rare diseases. Annual reports on Form 20-F, referenced in company legal notices, contain broader information on risk factors, business description, and financial statements.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand the significance of new 6-K submissions, annual reports, and other disclosures. Investors can use this page to monitor Telix’s ongoing reporting obligations, track how clinical and regulatory events are reflected in official filings, and review the company’s historical SEC record, including exhibits related to clinical trials, reimbursement decisions, and capital markets activity.
Telix Pharmaceuticals reports that the U.S. FDA has accepted its resubmitted New Drug Application for TLX101-Px (Pixclara), a PET imaging agent for glioma, and has assigned a PDUFA goal date of September 11, 2026.
TLX101-Px has Orphan Drug and Fast Track designations and is intended to help distinguish recurrent or progressive glioma from treatment-related changes in adults and children. Telix notes that its FY 2026 financial guidance does not include any revenue from TLX101-Px.
Telix Pharmaceuticals Limited has expanded its Board by appointing two additional Non-Executive Directors, effective May 11, 2026, as part of broader succession planning. Maria Rivas, MD brings more than 25 years of experience in late-stage clinical development and commercialization, including service as Chief Medical Officer at Pfizer.
William (Bill) Jellison adds over 30 years of corporate finance and audit committee leadership, having served as Vice President and CFO of Stryker and as a director for multiple U.S. public companies. Telix’s Interim Chair said these appointments support the company’s evolution as a dual-listed, global, commercial-stage biopharmaceutical business focused on radiopharmaceuticals for oncology and rare diseases.
Telix Pharmaceuticals reports strong first-quarter momentum, with unaudited Q1 2026 group revenue of US$230 million, up 24% year-over-year and 11% from Q4 2025. Precision Medicine revenue reached US$186 million, rising 23% year-over-year as Illuccix and Gozellix dose volumes and market share increased.
The company reaffirmed its FY 2026 revenue guidance of US$950–970 million and R&D expenditure guidance of US$200–240 million, indicating continued heavy investment in its pipeline. TMS third-party revenue was US$44 million, up 29% year-over-year.
Telix highlighted multiple late-stage pipeline advances, including Part 1 of the global Phase 3 ProstACT trial for TLX591-Tx meeting safety and dosimetry objectives with no new safety signals, first-patient-in for pivotal trials in brain cancer and glioblastoma, and regulatory progress for imaging agents TLX101-Px (NDA resubmission in the U.S. and MAA filing in Europe) and TLX250-Px (preparing a BLA resubmission after successful FDA Type A meetings). Corporate updates include appointing David Gill as a new Non-Executive Director, with an expectation he will become Chair.
Telix Pharmaceuticals Limited has appointed experienced life sciences executive David Gill as a Non-Executive Director as part of its board expansion and succession planning. His appointment is effective May 11, 2026, subject to grant of an Australian Director Identification number.
Gill is expected to become Chair in due course, succeeding Interim Chair Dr. Mark Nelson, who will remain on the board as a Non-Executive Director. Telix also announced that Genevieve Ryan resigned as Company Secretary effective April 2, 2026, with Shomalin Naidoo appointed interim Company Secretary and primary ASX Listing Rule contact from the same date.
Telix Pharmaceuticals Group Chief Financial Officer Darren Charlton Smith exercised previously granted share rights into ordinary shares. On March 29, 2026, he converted 1,111 share rights into 1,111 ordinary shares at an exercise price of $0.00 per share. These share rights were granted on January 1, 2025 and became vested and exercisable on March 5, 2026. Following the transaction, he directly holds 11,921 ordinary shares of Telix Pharmaceuticals Ltd, and the exercised share rights position has been fully used with no remaining derivative balance reported. No open-market sale occurred in this filing; it reflects a routine compensation-related option exercise that increases his direct share ownership.
Telix Pharmaceuticals’ Group Chief Medical Officer, Cade David Norman, has reported his existing equity interests in the company. He holds 373,133 Ordinary Shares directly, along with several derivative awards tied to Telix ordinary shares.
These include Performance Share Appreciation Rights over 78,189 underlying Ordinary Shares at A$4.9500 per share expiring on April 4, 2027, and 84,293 underlying Ordinary Shares at A$6.9000 per share expiring on December 21, 2027. He also holds Share Rights over 1,080 underlying Ordinary Shares expiring on March 31, 2028 and 11,486 underlying Ordinary Shares expiring on March 31, 2029. Footnotes state these awards were granted between April 2022 and March 2026, with vesting dates in 2025–2027 and that each Share Right represents the contingent right to receive one ordinary share, subject to continued employment and forfeiture if employment is terminated for cause.
Telix Pharmaceuticals Ltd director Nelson Mark Alexander has filed an initial Form 3 reporting his existing shareholdings. The filing shows indirect beneficial ownership of 3,628,750 Ordinary Shares held through MAN Holdings Pty Ltd, acting as trustee for the Nelson Hybrid Trust, of which he is a director and shareholder. This filing records his current position rather than any new share purchase or sale.
Telix Pharmaceuticals Ltd Group Chief Operating Officer Darren Joel Patti filed an initial ownership report showing existing equity interests in the company. The filing lists 25,558 Ordinary Shares held directly and 804 American Depositary Receipts, each convertible into one ordinary share according to the footnotes.
It also discloses derivative awards over ordinary shares, including Performance Share Appreciation Rights over 15,826 shares at $4.9500 per share and 27,448 shares at $6.9000, both with future expiration dates. Share Rights cover an additional 15,000, 12,541, and 15,000 underlying ordinary shares at a $0.0000 exercise price, with vesting and exercisability tied to continued service and future testing of results. The report records holdings only and does not show new market purchases or sales.
Telix Pharmaceuticals Ltd director Marie Elizabeth McDonald has filed an initial ownership report on Form 3. The filing shows an indirect holding of 3,719 Ordinary Shares held through Netwealth Investments Limited as custodian. This is a disclosure of existing holdings rather than a new share purchase or sale.